中国全科医学 ›› 2018, Vol. 21 ›› Issue (19): 2379-2383.DOI: 10.12114/j.issn.1007-9572.2018.19.023

• 专题研究 • 上一篇    下一篇

肠促胰素类药物对糖尿病患者动脉粥样硬化性心血管疾病作用的研究进展

徐远新,李强*   

  1. 150036黑龙江省哈尔滨市,哈尔滨医科大学附属第二医院内分泌与代谢病科
    *通信作者:李强,教授,博士生导师;E-mail:QiangLi26@126.com
  • 出版日期:2018-07-05 发布日期:2018-07-05
  • 基金资助:
    基金项目:国家自然科学基金资助项目(81170744,81370902)

The Effect of Incretin Mimetic Drugs on Atherosclerotic Cardiovascular Disease in Diabetic Patients

XU Yuan-xin,LI Qiang*   

  1. Department of Endocrine and Metabolic Diseases,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150036,China
    *Corresponding author:LI Qiang,Professor,Doctoral supervisor;E-mail:QiangLi26@126.com
  • Published:2018-07-05 Online:2018-07-05

摘要: 作为动脉粥样硬化性心血管疾病(ASCVD)的高危人群,糖尿病患者对既能降低血糖水平又能减少或不增加ASCVD患病风险的药物的需求逐渐增加。鉴于心肌细胞上存在胰高血糖素样肽1受体(GLP-1R),因此,肠促胰素类药物可能对糖尿病患者ASCVD产生作用。本文通过系统整理既往发表的国内外文献,对肠促胰素的结构与作用,肠促胰素对心肌细胞、心脏功能、血压、血脂水平等的影响进行综述,以期探讨肠促胰素类药物对糖尿病患者ASCVD的作用,为进一步研发既能降低血糖水平又起到保护心血管作用的药物提供依据,最终改善糖尿病患者尤其是合并ASCVD的患者的治疗效果和预后。

关键词: 糖尿病, 心血管疾病, 肠促胰素, 胰高血糖素样肽1, 二肽基肽酶4

Abstract: As a high-risk group of atherosclerotic cardiovascular disease(ASCVD),there is a growing demand for medications in patients with diabetes mellitus that could both reduce blood glucose as well as the prevalence of ASCVD,or at least may not increase it.In view of the presence of glucagon-like peptide 1 receptor(GLP-1R) on the cardiac myocytes,incretin mimetic drugs may play a role in ASCVD of diabetic patients.To explore the effect of incretin mimetic drugs on ASCVD in diabetic patients,this article systematically reviews previous published literatures at home and abroad to introduce the structure and function of incretin,and the effect of incretin on cardiac myocytes,cardiac function,blood pressure and blood lipid level.We hope to provide basis for further research and development of drugs that not only reduce blood glucose but also protect cardiovascular system,and ultimately improve the therapeutic effect and prognosis of diabetic patients,especially those with ASCVD.

Key words: Diabetes mellitus, Cardiovascular diseases, Incretin, Glucagon-like peptide 1, Dipeptidyl peptidase 4